Fact Meets Function

This study examined whether hydromethylthionine (a tau aggregation inhibitor related to methylene blue) could restore glutamate release deficits in tau transgenic mice, finding that the compound successfully rescued synaptosomal glutamate release impairments associated with tau pathology. The research demonstrates a mechanistic link between tau aggregation and synaptic glutamate dysfunction in a mouse model of tauopathy. *Evidence level: Animal model* (Note: The source listed this as “Human Clinical,” but the actual study design employed tau transgenic mice, making this an animal model investigation).

This human clinical study describes the design and dose selection rationale for a Phase 3 randomized controlled trial of hydromethylthionine mesylate (a methylene blue derivative), an oral tau aggregation inhibitor being investigated for Alzheimer’s disease treatment. Researchers selected a 16 mg/day dose based on prior pharmacokinetic, safety, and efficacy data from earlier phase trials, with the goal of inhibiting tau protein aggregation while maintaining tolerability. The article presents the scientific basis and trial design rather than reporting primary efficacy outcomes from the Phase 3 trial itself.

This human clinical study describes the treatment of Kleine-Levin Syndrome (a rare condition characterized by recurrent episodes of hypersomnia and behavioral changes) using intranasal photobiomodulation combined with methylene blue in individual patient cases. The report documents patient responses to this combined intervention approach, though specific efficacy data and outcome measures are not detailed in the provided information. As a human clinical case report or small series, this represents lower-level evidence compared to randomized controlled trials.

This open-label randomized controlled clinical trial (human clinical evidence) investigated whether methylene blue could reduce early postoperative cognitive dysfunction (POCD) in elderly patients undergoing major non-cardiac surgery. The study found that methylene blue treatment reduced the incidence of early POCD in this patient population compared to control. This represents direct clinical evidence from a human trial, though the open-label design (where participants and researchers knew treatment assignment) represents a moderate strength of evidence compared to blinded trials.

This human clinical study evaluated hydromethylthionine (a formulation of methylene blue) as a potential therapeutic agent for Alzheimer’s disease, examining its pharmacological properties and clinical efficacy based on available evidence. The research assessed hydromethylthionine’s mechanism of action, safety profile, and effectiveness in slowing cognitive decline in Alzheimer’s patients, contributing to the expert analysis of its role among treatment options. This evidence represents human clinical research on a pharmaceutical intervention for neurodegenerative disease.